Mesenchymal stem cells and COVID-19: the process of discovery and of translation.
Biomater Transl
; 2(4): 307-311, 2021.
Article
in English
| MEDLINE | ID: covidwho-1934625
ABSTRACT
Mesenchymal stem cells were developed as a cell-based therapeutic in the 1990's. The translation of culture expanded mesenchymal stem cells from a basic science focus into a modern therapeutic has taken 30 years. The current state of the basic science information argues that mesenchymal stem cells may be curative for coronavirus disease 2019 (COVID-19). Indeed, early small-scale clinical trials have shown positive results. The issue raised is how to assemble the resources to get this cell-based therapy approved for clinical use. The technology is complex, the COVID-19 viral infections are life threatening, the cost is high, but human life is precious. What will it take to perfect this potentially curative technology?
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Biomater Transl
Year:
2021
Document Type:
Article
Affiliation country:
Biomatertransl.2021.04.006
Similar
MEDLINE
...
LILACS
LIS